MRS of Psychiatric Disorders

Magnetic Resonance Spectroscopy: Tools for Neuroscience Research and Emerging Clinical Applications

Volumn , Issue , 2013, Pages 222-228

  Taylor, Matthew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

GABA; Glutamate; Mood disorders; N acetylaspartate; Neurotransmitters; Psychotic disorders; Schizophrenia

Indexed keywords

EID: 84902237815     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-401688-0.00016-1     Document Type: Chapter

References (58)

1. Alcaro A., Panksepp J., Witczak J., Hayes D.J., Northoff G. Is subcortical-cortical midline activity in depression mediated by glutamate and GABA? A cross-species translational approach. Neuroscience and Biobehavioral Reviews 2010, 34(4):592-605.
2. Auer D.P., Pütz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry 2000, 47(4):305-313.
3. Bassett D.S., Bullmore E.T. Human brain networks in health and disease. Current Opinion in Neurology 2009, 22(4):340-347.
4. Beardslee W.R., Versage E.M., Gladstone T.R. Children of affectively ill parents: a review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry 1998, 37(11):1134-1141.
5. Bechdolf A., Nelson B., Cotton S.M., Chanen A., Thompson A., Kettle J., et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. Journal of Affective Disorders 2010, 127(1-3):316-320.
6. Bhagwagar Z., Cowen P.J. -It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychological Medicine 2008, 38(3):307-313.
7. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Ashworth F., Sule A., et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biological Psychiatry 2007, 61(6):806-812.
8. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biological Psychiatry 2011, 69(5):495-503.
9. Chugani D.C. Neuroimaging and neurochemistry of autism. Pediatric Clinics of North America 2012, 59(1):63-73.
10. Constant A., Castera L., Dantzer R., Couzigou P., de Ledinghen V., Demotes-Mainard J., et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Journal of Clinical Psychiatry 2005, 66(8):1050-1057.
11. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 2006, 26(4-6):365-384.
12. Diez-Quevedo C., Masnou H., Planas R., Castellví P., Giménez D., Morillas R.M., et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2011, 72(4):522-528.
13. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010, 67(5):446-457.
14. Egerton A., Brugger S., Raffin M., Barker G.J., Lythgoe D.J., McGuire P.K., et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 2012, 37(11):2515-2521.
15. Egerton A., Fusar-Poli P., Stone J.M. Glutamate and psychosis risk. Current Pharmaceutical Design 2012, 18(4):466-478.
16. Egerton A., Stone J.M. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Current Pharmaceutical Biotechnology 2012, 13(8):1500-1512.
17. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 2012, 69(3):220-229.
18. Fusar-Poli P., Valmaggia L., McGuire P. Can antidepressants prevent psychosis?. Lancet 2007, 370(9601):1746-1748.
19. Goldberg D.P., Andrews G., Hobbs M.J. Where should bipolar disorder appear in the meta-structure?. Psychological Medicine 2009, 39(12):2071-2081.
20. Goodwin G.M. Bipolar depression and treatment with antidepressants. British Journal of Psychiatry 2012, 200(1):5-6.
21. Griffith H.R., Stewart C.C., den Hollander J.A. Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. International Review of Neurobiology 2009, 84:105-131.
22. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 2005, 10(1):40-68.
23. Hasler G., Neumeister A., van der Veen J.W., Tumonis T., Bain E.E., Shen J., et al. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biological Psychiatry 2005, 58(12):969-973.
24. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry 2007, 64(2):193-200.
25. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 2002, 7(9):942-947.
26. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Archives of General Psychiatry 2012, 69(5):449-459.
27. Kempton M.J., Geddes J.R., Ettinger U., Williams S.C.R., Grasby P.M. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Archives of General Psychiatry 2008, 65(9):1017-1032.
28. Kempton M.J., Salvador Z., Munafo M.R., Geddes J.R., Simmons A., Frangou S., et al. Structural Neuroimaging Studies in Major Depressive Disorder: Meta-analysis and Comparison With Bipolar Disorder. Archives of General Psychiatry 2011, 68(7):675-690.
29. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry 1998, 172:110-120.
30. Li C.-T., Bai Y.-M., Huang Y.-L., Chen Y.-S., Chen T.-J., Cheng J.-Y., et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. British Journal of Psychiatry 2012, 200(1):45-51.
31. Lim C., Olson J., Zaman A., Phelps J., Ingram K.D. Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis C infection. Journal of Clinical Gastroenterology 2010, 44(7):e141-146.
32. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65(9):732-741.
33. Mitchell P.B., Goodwin G.M., Johnson G.F., Hirschfeld R.M.A. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders 2008, 10(1 Pt 2):144-152.
34. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 2011, 70(1):88-96.
35. Ongür D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biological Psychiatry 2008, 64(8):718-726.
36. Owen M.J., Craddock N., Jablensky A. The genetic deconstruction of psychosis. Schizophrenia Bulletin 2007, 33(4):905-911.
37. Price J.L., Drevets W.C. Neural circuits underlying the pathophysiology of mood disorders. Trends in Cognitive Sciences 2012, 16(1):61-71.
38. Raison C.L., Borisov A.S., Broadwell S.D., Capuron L., Woolwine B.J., Jacobson I.M., et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Journal of Clinical Psychiatry 2005, 66(1):41-48.
39. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 2006, 27(1):24-31.
40. Reynolds G.P., Harte M.K. The neuronal pathology of schizophrenia: molecules and mechanisms. Biochemical Society Transactions 2007, 35(2):433.
41. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.-T., Appel M., Rothman D.L., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 2004, 61(7):705-713.
42. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62(1):63-77.
43. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology 2007, 18(5-6):391-418.
44. Shepherd A.M., Laurens K.R., Matheson S.L., Carr V.J., Green M.J. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neuroscience and Biobehavioral Reviews 2012, 36(4):1342-1356.
45. Soeiro-de-Souza M.G., Salvadore G., Moreno R.A., Otaduy M.C.G., Chaim K.T., Gattaz W.F., et al. Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar i disorder. Neuropsychopharmacology 2013, 38(3):468-475.
46. Stone J.M., Day F., Tsagaraki H., Valli I., McLean M.A., Lythgoe D.J., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biological Psychiatry 2009, 66(6):533-539.
47. Stone J.M., Howes O.D., Egerton A., Kambeitz J., Allen P., Lythgoe D.J., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry 2010, 68(7):599-602.
48. Tavares R.G., Tasca C.I., Santos C.E.S., Alves L.B., Porciúncula L.O., Emanuelli T., et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochemistry International 2002, 40(7):621-627.
49. Taylor M.J., Godlewska B.R., Norbury R., Selvaraj S., Near J., Cowen P.J. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. International Journal of Neuropsychopharmacology 2012, 15(10):1541-1546.
50. Taylor M.J., Mannie Z.N., Norbury R., Near J., Cowen P.J. Elevated cortical glutamate in young people at increased familial risk of depression. International Journal of Neuropsychopharmacology 2011, 14(2):255-259.
51. Taylor M.J., Near J., Cowen P.J. Neurochemical changes in an immunologically-induced high risk state for mood disorder: interferon-alpha treatment of chronic hepatitis C viral infection. Journal of Psychopharmacology 2011, 25(S8):A13.
52. Taylor M.J., Selvaraj S., Norbury R., Jezzard P., Cowen P.J. Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. Journal of Affective Disorders 2009, 119(1-3):186-189.
53. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374(9690):635-645.
54. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000, 157(1):16-25.
55. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophrenia Research 2003, 60(1):21-32.
56. Yüksel C., Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biological Psychiatry 2010, 68(9):785-794.
57. Zarate C., Machado-Vieira R., Henter I., Ibrahim L., Diazgranados N., Salvadore G. Glutamatergic modulators: the future of treating mood disorders?. Harvard Review of Psychiatry 2010, 18(5):293-303.
58. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophrenia Bulletin. 2012, [Epub ahead of print].